EP
FDMT icon

Essential Partners’s 4D Molecular Therapeutics FDMT Stock Holding History

Essential Partners’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40 Sell
3
-101
-97% -$984 ﹤0.01% 2804
2026
Q1 		$968 Hold
104
– – ﹤0.01% 2257
2025
Q4 		$780 Hold
104
– – ﹤0.01% 2106
2025
Q3 		$904 Buy
104
+3
+3% +$18 ﹤0.01% 2049
2025
Q2 		$375 Buy
+101
New +$355 ﹤0.01% 1776

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Essential Partners's FDMT Position: Q2 2026 in Review

Essential Partners reduced its 4D Molecular Therapeutics (FDMT) stake by 97% in Q2 2026, selling an estimated $984 and leaving 3 shares worth $40. The position accounts for ﹤0.01% of the portfolio, ranked #2804.

Essential Partners first reported a position in FDMT in Q2 2025 and has held it in 5 quarters since. The position peaked at $968 in Q1 2026. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Essential Partners held 3 shares of 4D Molecular Therapeutics worth $40 as of Q2 2026.
  • Essential Partners sold 101 4D Molecular Therapeutics shares in Q2 2026, an estimated $984.
  • 4D Molecular Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2804 holding.
  • Essential Partners first reported a position in 4D Molecular Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's 4D Molecular Therapeutics position peaked at $968 in Q1 2026.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.